CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

This study is testing a new drug called CLN-049 in people with acute myeloid leukemia (AML) or a pre-leukemia condition called myelodysplastic syndrome (MDS) that has come back or stopped responding to treatment. CLN-049 is a type of antibody designed to direct the immune system to attack leukemia cells. **You may be eligible if...** - You are 18 or older and have AML or MDS that has returned or is not responding to available treatments - You have tried approved therapies or declined them after being offered - Your blood counts and organ function meet minimum requirements - You are in reasonably good health (ECOG performance status 0–2) **You may NOT be eligible if...** - You have a type of leukemia called acute promyelocytic leukemia (APL) - You have active leukemia in your brain or spinal fluid - You have recently had an organ transplant, stem cell transplant with active graft-versus-host disease, or total body irradiation - You have HIV, active hepatitis B or C, or active COVID-19 - You have received CAR-T cell therapy in the past - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.